Navigation Links
New Study Conducted To Evaluate The Success Of The Federal governments Funds For HIV/AIDS

The U.S. federal government plans to spend in this financial year $21 billion for HIV/AIDS research, treatment, prevention, and related activities//. Among doubts on whether this enormous expenditure is paying off, a new study was conducted which seemingly indicated that the expenditure is paying off and is more successful than of what was previously thought. The study that is now available on line is due to be published in the JULY edition of The Journal of Infectious Diseases, Rochelle P. Walensky, MD, MPH, Kenneth Freedberg , MD, MSc and colleagues at Massachusetts General Hospital and other centers, conducted the study, which appears at a time the world is contemplating the 25-year anniversary of the first reported cases of AIDS and celebrating the 10-year anniversary of the use of multi-drug antiretroviral combinations for the treatment of HIV infections (also known as highly active antiretroviral therapy or HAART).

To analyze the impact of HAART on patient survival, the investigators used a computer simulation model to examine national surveillance and efficacy data for newly diagnosed adult AIDS patients under care in the United States from 1989 to 2003. They divided those years into 'eras' corresponding to specific advances in AIDS care, and then used the simulation model to determine per-person survival time for each era, compared to the absence of treatment.

The results: Per-person survival increased by three months in 1989-92 and then by two years in 1993-95; both eras were characterized by the introduction of certain measures to prevent opportunistic infections. But in the four HAART eras spanning 1996 to 2003, per-person survival increased by approximately eight, 11, 12, and 13 years. Over the past 10 years, the investigators concluded, widespread adoption of HAART regimens, in addition to prophylaxis, led to at least 3 million years of life saved in the United States. Moreover, since approximately 25 percent of those infected wi
'"/>




Page: 1 2

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer

Post Your Comments:
(Date:11/29/2009)...begin to form between brain cells almost immediate...dy published this week in Nature . Led by researc...the study involved detailed observations of the re...ng motor learning. , The researchers studied mic...get a seed. They observed rapid growth of structur...
(Date:11/29/2009)...eatment equals a $41,000 pay raise, researchers sa... -- Psychological therapy may be much more effecti...winning a lottery prize, suggests an English study...eople who provided information about their mental ...s from a $1,329 course of therapy was so significa...
(Date:11/29/2009)...l healthcare,s uncertain future and rising costs o...e. Affordable Acupuncture Scottsdale answers the c...9, 2009 -- Affordable Acupuncture, LLC opened in S... met with enthusiasm and gratitude. Its increasing... two things, need and cost. "As far as I&rsq...
(Date:11/28/2009)... consider change after 30-minute psychosocial inte...7 (HealthDay News) -- A program that gets persiste...their dangerous behavior may lead to significant a..., The new study included 184 men and women with ...o were randomly assigned to one of two interventio...
(Date:11/27/2009)... GSI Group Inc. (Pink Sh...on technology products and semiconductor systems, ...any,s shareholders has been scheduled for Friday, ...ing will be announced in due course. As previousl...tice from Stephen Bershad, a holder of greater tha...
Breaking Medicine News(10 mins):Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:Psychotherapy Can Boost Happiness More Than Money: Study 2Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:GSI Group Calls Shareholders Meeting 2
.... 9 Global multiservice public relations,agency W... panel discussion,titled "Healthcare Communication...Highly Regulated Environment." The presentation wi...eg/events/healthcare-webcast.aspx . , Interest...
...., Feb. 9 VNUS(R) Medical,Technologies, Inc. (Nas...es for,the minimally invasive treatment of venous ...nt at the Roth 21st Annual OC Growth Stock Confere...fficer and Vice,President of Finance and Administr...
...irin Announce Support of National Women,s Heart He...ORRISTOWN, N.J., Feb. 9 Bayer HealthCare LLC, the... support of WomenHeart, the nation,s only educatio...An estimated 44 million American women live with o...
...mulation of clopidogrel, the active ingredient in ... PRUSSIA, Pa., Feb. 9 Prism Pharmaceuticals ann...study of PM103, a novel intravenous formulation of...College of Cardiology (ACC) on March 29-31, 2009. ...
...led as One of the Top Achievements in 50 Years of ...(R) Brand, the original Rh immune globulin product...ing Rh-negative women in the prevention of Hemolyt...rld,s first injectable treatment to prevent the di...
..., Feb. 9 Shopko announced today that it won,first...he Year design,competition for the design of its n...in, early last year. Shopko,s new store design wil...g retail design firm Chute Gerdeman Retail in,conj...
Other Medicine News:Health News:Healthcare Online Regulations to Be Discussed in Live Event and Webcast Hosted by Waggener Edstrom Worldwide 2Health News:Bayer Consumer Care Joins Forces with WomenHeart to Fight Heart Disease 2Health News:Bayer Consumer Care Joins Forces with WomenHeart to Fight Heart Disease 3Health News:Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology 2Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 2Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 3Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 4Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 5Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 6Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 7Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 8Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 9Health News:New Shopko Store Design Takes Top Honors 2Health News:New Shopko Store Design Takes Top Honors 3
(Date:11/27/2009)..., SALT LAKE CITY, Nov. 27 /PRNewswire-FirstCall/ ...ems, Inc. (NYSE: VAR ), a premier supplier of X-...will exhibit its full range of detectors at the RS...9 - December 3, 2009. Varian will also be exhibit...as well as specialized cancer treatment technologi...
(Date:11/26/2009)..., JOHANNESBURG, South Africa, Nov. 26 /PRNewswir...ompany of the Year Award in the Generic Pharmaceut...ica Limited. ,, (Logo: http://www.newscom.com/...ny of the Year Award, the following criteria were ...st key competitors: growth strategy and implementa...
(Date:11/25/2009)..., LOVELAND, Colo., Nov. 25 /PRNewswire-FirstCall/...g provider of advanced diagnostic and specialty ...ay agreements with Roche Diagnostics Corporation f... consumables for the veterinary market. ,, (...22/HESKALOGO ) ,, "Heska and Roche share the sa...
Breaking Medicine Technology:Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Siemens Hearing Instruments Introduces Affordable and Flexible Pure 300 50492 1Siemens Hearing Instruments Introduces Affordable and Flexible Pure 300 50492 2Women with endometriosis need special care during pregnancy to avoid risk of premature birth 9079 1Women with endometriosis need special care during pregnancy to avoid risk of premature birth 9079 2New PICC Mimics Nature 50488 1New PICC Mimics Nature 50488 2
...quarter 2008 -, CAMBRIDGE, Mass., Sept. 18 Mille... announced that the interim,analysis results of th...,patients with newly diagnosed multiple myeloma sh...ednisone (VMP) demonstrated a highly statistically... including time-to-disease,progression, complete r...
...ries (NYSE: FRX ) announced today that single dos...onchodilatory response in 17 patients,with COPD ac...today at the,European Respiratory Society (ERS) An....newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) ... values - important,measures of lung function - we...
Other Medicine Technology:Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 2Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 3Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 4Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 5Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 6Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 2Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 3Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 4Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 5
Machat Corneal Spatula
Koch Phacoemulsification Spatula
Hirschman Iris Lens Spatula
Lane Lasik Spatula
Medicine Products: